CANBRIDGE-B released its interim results, with a profit of HKD 59.238 million during the period, turning from a loss to a profit year-on-year
CANBRIDGE-B announced its interim results for the period ending June 30, 2025, with a profit of HKD 59.238 million, turning a profit compared to a loss in the same period last year. Revenue was HKD 22.248 million, a decrease of 50.33% year-on-year. The announcement pointed out that the decline in revenue was mainly due to the company's strategic focus on rare diseases, with the sales of Healan® in Taiwan being halted. Additionally, proactive inventory management was implemented in the first half of 2025, reducing the inventory of Mireb® . Earnings per share were HKD 0.14
According to the Zhitong Finance APP, CANBRIDGE-B (01228) announced its interim results for the six months ending June 30, 2025, reporting revenue of HKD 22.248 million, a year-on-year decrease of 50.33%; the profit for the period was HKD 59.238 million, compared to a loss of HKD 247 million in the same period last year; earnings per share were HKD 0.14.
The announcement stated that the decrease in revenue was mainly due to the company's original plan to strategically focus on rare diseases in 2021, and the termination of the distribution agreement for HeLianAn® at the end of 2024 led to the cessation of HeLianAn® sales in Taiwan. Excluding the sales of HeLianAn® in Taiwan, our revenue decreased by HKD 1.7 million or 6.9% compared to the same period in 2024, mainly due to CANBRIDGE's implementation of proactive inventory management in the first half of 2025 and the reduction of MaiRuBei® inventory in the channels
